Dwight Fitch, MD
Radiation Oncology · Bradenton, FLNPI 1871540278
Payments from drug & device makers
Across 46 payments — averaging $84.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- West Therapeutics Development, LLC$3K
- Novocure Inc.$317
- AstraZeneca$149
- Myriad Genetic Laboratories, Inc.$142
- Sumitomo Pharma America, Inc.$117
- Nalu Medical, Inc.$111
- plus $543 from 10 others
What the payments were for
- Speaking & faculty fees$2,50064%
- Food & beverage$1,32634%
- Education$682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| West Therapeutics Development, LLC | 2 | $2,516 |
| Novocure Inc. | 9 | $317 |
| AstraZeneca | 4 | $149 |
| Myriad Genetic Laboratories, Inc. | 4 | $142 |
| Sumitomo Pharma America, Inc. | 7 | $117 |
| Nalu Medical, Inc. | 1 | $111 |
| Boston Scientific | 3 | $106 |
| Blue Earth Diagnostics | 4 | $105 |
| Novartis | 4 | $99 |
| Abiomed | 1 | $60 |
| Bioprotect Medical, Inc. | 1 | $36 |
| Myovant Sciences Inc. | 2 | $35 |
| Teleflex LLC | 1 | $35 |
| Gilead | 1 | $25 |
| Merck | 1 | $22 |
| Kerecis Limited | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lazanda$2,500
- Nalu Neurostimulation System$111
How this compares
$3,895 in reported general payments places this provider in the 75th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $1,349 |
| SsdSilver Sulfadiazine | 18 | $592 |
| Lidocaine Hcl ViscousLidocaine Hcl | 17 | $459 |
| Dexamethasone | 16 | $404 |
| Tamsulosin Hcl | 23 | $271 |
| Triamcinolone Acetonide | 45 | $200 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Bradenton
- Charles KunosMiami$3.2M
- Rupesh KotechaMiami$2M
- Alexander EngelmanTampa$1.1M
- John SylvesterLakewood Ranch$999K
- Kamran AhmedTampa$975K
- Michael ChuongMiami$868K
- Tithi BiswasGainesville$640K
- Daniel TrifilettiJacksonville$606K
- Marcus BredelMiami$578K
- Kathryn HitchcockGainesville$504K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.